Tenon Medical, Inc. (TNON) Stock Analysis

Why this analysis is different

• A sector-relative MoonshotScore — five pillars (business quality, financial safety, valuation, growth durability, momentum) re-ranked nightly against the full universe of US-listed common stocks.
• An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
• Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.

Tenon Medical, Inc. (TNON) Healthcare & Pipeline Overview

Tenon Medical, Inc. specializes in medical devices for lower back pain, primarily the Catamaran SI-Joint Fusion System. This system offers a unique approach to sacroiliac joint fusion, targeting a significant market need within the broader medical device industry, but faces competition and market adoption challenges.

What Is the Investment Thesis for TNON?

Tenon Medical, Inc. presents a focused investment opportunity within the medical device sector, centered around its Catamaran SI-Joint Fusion System. The company's gross margin of 52.4% indicates potential for profitability as sales scale. Key value drivers include increasing adoption of the Catamaran system by surgeons, expansion of the company's sales and marketing efforts, and potential for future product development in the spinal disorder space. However, the company's negative ROE of -197.3% and a debt-to-equity ratio of 4.50 highlight significant financial risks. The company's market capitalization is $0.01B. Upcoming catalysts include potential positive clinical data releases and strategic partnerships to expand market reach. Investors should carefully weigh the growth potential against the financial risks and competitive landscape.

Based on FMP financials and quantitative analysis

TNON Key Highlights

Gross Margin of 52.4% indicates potential for profitability as sales volume increases.

• Negative ROE of -197.3% reflects current financial challenges and the need for improved profitability.
• Debt-to-Equity Ratio of 4.50 signifies a high level of financial leverage, increasing financial risk.
• Market Capitalization of $3.51M indicates a small-cap company with significant growth potential but also higher volatility.
• Beta of 1.25 suggests the stock is more volatile than the overall market.

Who Are TNON's Competitors?

TNON is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are TNON's Key Strengths?

Innovative Catamaran SI-Joint Fusion System.

• Minimally invasive surgical approach.
• Focus on a specific market niche (SI joint disorders).
• Potential for strong gross margins.

What Are TNON's Weaknesses?

Limited financial resources.

• Small sales and marketing team.
• Dependence on a single product line.
• Negative ROE.

What Could Drive TNON Stock Higher?

Publication of clinical data supporting the Catamaran SI-Joint Fusion System.

• Potential strategic partnerships with larger medical device companies.
• Expansion of the sales and marketing team.
• Increasing awareness of SI joint disorders among surgeons and patients.

What Are the Key Risks for TNON?

Financial-distress signal — its Altman Z-Score of -16.43 sits in the distress zone (elevated bankruptcy risk).

• Inconsistent delivery — missed Wall Street EPS estimates in 5 of the last 8 reported quarters.
• Weak fundamentals — a Piotroski F-Score of 3/9 flags soft profitability, leverage or efficiency.
• Competition from established medical device companies with greater resources.
• Reimbursement challenges from insurance providers.
• Product liability claims.
• Dependence on a single product line.
• Limited financial resources.

What Are the Growth Opportunities for TNON?

• Expansion of Sales and Marketing Efforts: Tenon Medical can drive growth by expanding its sales and marketing team to reach a wider network of spine surgeons and pain management specialists. This includes increasing participation in industry conferences, conducting training workshops, and developing targeted marketing campaigns to highlight the benefits of the Catamaran SI-Joint Fusion System. The market for SI joint fusion is estimated to be substantial, offering significant revenue potential for Tenon Medical as it increases market penetration. Timeline: Ongoing.
• Strategic Partnerships and Distribution Agreements: Forming strategic partnerships with larger medical device companies or establishing distribution agreements with established distributors can significantly expand Tenon Medical's market reach and accelerate sales growth. This would allow the company to leverage the existing infrastructure and relationships of its partners to access new markets and customers. The timeline for securing such partnerships is estimated to be within the next 12-24 months.
• New Product Development and Innovation: Investing in research and development to develop new products and improve existing technologies can drive long-term growth for Tenon Medical. This includes exploring opportunities to expand the Catamaran system to address other spinal disorders or developing complementary products for pain management. The timeline for new product development is estimated to be 2-3 years.
• Geographic Expansion: Expanding into new geographic markets, such as Europe and Asia, represents a significant growth opportunity for Tenon Medical. This would involve obtaining regulatory approvals in these markets and establishing sales and distribution networks. The global market for spinal implants and surgical devices is substantial, offering significant revenue potential for Tenon Medical as it expands its geographic reach. Timeline: 3-5 years.
• Clinical Data and Publications: Generating positive clinical data and publishing peer-reviewed articles on the Catamaran SI-Joint Fusion System can enhance the credibility and adoption of the product among surgeons. This includes conducting clinical trials to demonstrate the safety and efficacy of the system and publishing the results in leading medical journals. Positive clinical data can also support reimbursement coverage from insurance providers. Timeline: Ongoing.

What Are TNON's Competitive Advantages?

• Proprietary Technology: The Catamaran SI-Joint Fusion System represents a unique and patented approach to SI joint fusion.
• Clinical Data: Positive clinical data supporting the safety and efficacy of the Catamaran system can create a competitive advantage.
• Surgeon Training and Education: Providing comprehensive training and education to surgeons on the use of the Catamaran system can foster brand loyalty.
• Established Relationships: Building strong relationships with spine surgeons and pain management specialists can create a barrier to entry for competitors.

What Does TNON Do?

Tenon Medical, Inc., founded in 2012 and headquartered in Los Gatos, California, is a medical device company dedicated to transforming the treatment of lower back pain. The company's core focus is on developing and commercializing innovative surgical solutions for sacroiliac (SI) joint disorders, a significant cause of chronic lower back pain. Their flagship product, the Catamaran SI-Joint Fusion System, represents a minimally invasive approach to SI joint fusion, utilizing a titanium implant designed to stabilize and fuse the joint. This system aims to provide lasting pain relief and improved quality of life for patients suffering from SI joint dysfunction. The Catamaran Fixation Device is another key offering, designed to transfix the SI Joint along its longitudinal axis, providing additional stability. Tenon Medical's strategic focus is on expanding the adoption of its Catamaran system among spine surgeons and pain management specialists, while also exploring opportunities to develop and commercialize complementary products for the treatment of spinal disorders. The company operates primarily in the United States, targeting a large and growing market of patients seeking relief from chronic lower back pain.

What Products and Services Does TNON Offer?

• Develops and markets the Catamaran SI-Joint Fusion System for treating lower back pain.
• Offers a minimally invasive surgical approach to sacroiliac joint fusion.
• Provides the Catamaran Fixation Device to stabilize the SI Joint.
• Focuses on treating SI Joint disorders, a common cause of lower back pain.
• Utilizes titanium implants for SI joint fusion.
• Aims to improve the quality of life for patients with chronic lower back pain.

How Does TNON Make Money?

• Generates revenue through the sale of the Catamaran SI-Joint Fusion System and related surgical instruments.
• Targets spine surgeons and pain management specialists as primary customers.
• Employs a direct sales force and distribution network to reach customers.
• Focuses on securing reimbursement coverage from insurance providers for its products.

What Industry Does TNON Operate In?

Tenon Medical operates within the medical device industry, specifically targeting the market for spinal implants and pain management solutions. The competitive landscape includes established players like Medtronic and Stryker, as well as smaller, specialized companies. Tenon Medical aims to differentiate itself through its unique Catamaran SI-Joint Fusion System, offering a minimally invasive approach to SI joint fusion.

Who Are TNON's Key Customers?

• Spine surgeons who perform SI joint fusion procedures.
• Pain management specialists who treat patients with chronic lower back pain.
• Hospitals and surgical centers that offer SI joint fusion surgery.
• Patients suffering from SI joint disorders and chronic lower back pain.

Tenon Medical, Inc. (TNON) Valuation Context

Valued at $3.51M, TNON is classified as a micro-cap stock. Relative to its peer group, TNON's quantitative score of 17/100 is below the peer average of 66/100.

TNON Revenue & Earnings Trend

In Q2 2026, TNON generated $1.3M in top-line revenue, marking a sequential decrease of 7.3%. The company recorded a net loss of $4.0M, with diluted EPS of $-12.35. Revenue has contracted over three consecutive quarters, which investors in this micro-cap Healthcare stock should monitor closely. Across the four most recent quarters, TNON averaged $-11.57 in diluted EPS.

Company Profile

Tenon Medical, Inc. operates in the Medical - Devices industry within the Healthcare sector. It is headquartered in Los Gatos, US. The company is led by CEO Steven Foster. TNON has traded publicly since 2022.

Key Financial Metrics

Return on assets is -96.5%, showing how much profit it generates from its asset base. A current ratio of 1.03 indicates the company holds enough short-term assets to cover its near-term obligations.

Tenon Medical, Inc.'s Piotroski F-Score is 3/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -16.43 places it in the distress zone, a signal of elevated financial risk.

Tenon Medical, Inc. has missed Wall Street's EPS estimate in 5 of its last 8 reported quarters — a mixed record worth weighing. Reported results have landed about 9.4% below estimates on average.

Wall Street analysts project Tenon Medical, Inc. revenue of about $6.6M for fiscal 2026, with EPS near $-0.84.

TNON Financials

TNON Latest News

TNON Analyst Consensus

TNON MoonshotScore

What Investors Ask About Tenon Medical, Inc. (TNON) — Healthcare

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources